Retatrutide vs Tirzepatide vs Semaglutide

How do the three compounds compare at a glance?

Molecular weights are approximate and are given for identity-verification context — the value a mass-spectrometry result on a Certificate of Analysis should be consistent with.

What distinguishes each compound?

Semaglutide is the reference GLP-1 mono-agonist and the simplest pharmacology of the three — a useful baseline for any comparison. It is a GLP-1 analogue, meaning its peptide backbone derives from GLP-1 itself, modified for protease resistance and extended circulation. Everything else in the class can be described in terms of what it adds to this foundation.

Tirzepatide adds GIP-receptor agonism to the GLP-1 arm, making it the first widely studied dual incretin agonist. The addition of the GIP axis is the whole story of what separates it from semaglutide. Structurally it marks a shift: rather than extending a GLP-1 analogue, it is built on a GIP-based backbone that has been given GLP-1 activity — the same architectural approach retatrutide later took.

Retatrutide adds a third arm — glucagon-receptor agonism — on top of the GIP/GLP-1 dual base. It is the most receptor-complex of the three and the only one still investigational. The glucagon arm is the defining and most-discussed point of difference, because glucagon classically raises blood glucose while the incretin arms lower it; see the mechanism-of-action page on retatrutide’s receptor pharmacology for why glucagon agonism is added despite that apparent tension.

How did the class evolve from one receptor to three?

The three compounds are best understood as successive answers to the same question rather than as competing products. The underlying idea — that gut hormones released in response to eating could be harnessed pharmacologically — dates back to the identification of the incretin effect, the observation that oral glucose provokes a substantially larger insulin response than an equivalent intravenous dose. Something in the gut was signalling to the pancreas.

GLP-1 was the first of those signals to be translated into a viable compound class. The engineering problem was never receptor binding; it was duration. Native GLP-1 is degraded by dipeptidyl peptidase-4 within minutes, so the entire first generation of this field was effectively a protein-engineering exercise in making an incretin last long enough to be useful. Semaglutide represents the mature solution to that problem.

Once duration was solved, the question shifted from how long to how many. Tirzepatide tested whether adding a second incretin axis changed the profile, and retatrutide extends that logic to a third receptor that is not an incretin at all. Each step adds a mechanistically distinct pathway rather than more of the same activity — which is also why each step raises new questions about how the arms interact rather than simply scaling the previous result.

It would be a mistake to read this progression as a straightforward ladder where more receptors is necessarily better. Additional receptor arms mean additional physiology engaged, and the field is still establishing what each combination does. The existence of GLP-1/glucagon dual agonists that deliberately omit GIP — covered below — is direct evidence that the optimal combination is an open question rather than a settled one.

How do they differ structurally?

All three face the same fundamental engineering problem. Native incretin hormones are degraded within minutes by dipeptidyl peptidase-4 (DPP-4) and cleared rapidly by the kidneys, so an unmodified peptide would be useless as a weekly-cadence compound. Each solves this the same way: non-coded amino acid substitutions to resist enzymatic degradation, plus a fatty-acid chain that promotes reversible binding to serum albumin.

Albumin binding is the key mechanism. A peptide bound to albumin is shielded from renal filtration and acts as a slowly-released circulating reservoir, converting a half-life measured in minutes into one measured in days. The three compounds differ in the specific fatty-acid chemistry used — semaglutide employs a C18 diacid linker, while tirzepatide and retatrutide use C20 diacid chemistry — but the strategy is shared across the class.

The more meaningful structural divergence is the backbone. Semaglutide is recognisably a GLP-1 molecule. Tirzepatide and retatrutide are, in structural terms, modified GIP analogues that have been given additional receptor activities through targeted substitution. That is a different design philosophy: rather than broadening a GLP-1 agonist, both start from GIP and build outward.

What other compounds are in this class?

The class is broader than these three, and a comparison restricted to the best-known names can give a misleading impression of how narrow the field is. Several other multi-agonists are in development:

Notably, the GLP-1/glucagon dual agonists (survodutide, mazdutide) represent a different combinatorial choice from tirzepatide’s GIP/GLP-1 pairing — they add the glucagon arm while omitting GIP. That the field is exploring several distinct receptor combinations rather than converging on one is itself informative about how unsettled the underlying pharmacology remains.

Why do molecular weights matter when comparing these compounds?

In a research setting the molecular weights in the comparison table are not incidental detail — they are the reference values against which identity is confirmed. Mass spectrometry establishes identity by measuring the intact molecular mass and comparing it against the theoretical mass of the intended target. If a certificate reports an observed mass that corresponds to roughly 4,114 Da when the label claims retatrutide at approximately 4,731 Da, the material is not what the label says regardless of how high the accompanying purity figure is.

This matters commercially as well as analytically. These three compounds are similar enough in class and appearance — all lyophilised white powders of comparable molecular size — that substitution is a realistic failure mode in an unregulated market, and substituting a cheaper approved-class peptide for an investigational one is a known pattern. The molecular weight is the check that catches it, which is why identity confirmation by mass spectrometry is not optional alongside a purity figure.

How to read that confirmation on a certificate — and what mass tolerance to expect from different instrument classes — is covered in our guide to evaluating a research peptide supplier.

Why does this page not compare weight-loss results?

Two reasons, one methodological and one regulatory.

The methodological reason is that there are no published head-to-head trials comparing all three compounds directly. Any comparison of reported figures means comparing separate trials with different participant populations, different inclusion criteria, different durations, different endpoints, and different statistical estimands. Cross-trial comparison of this kind is informative context, but it is not a controlled race, and presenting it as one would misrepresent the evidence.

The regulatory reason is that retatrutide is an investigational compound supplied for laboratory research use. Framing a comparison around which compound produces better human outcomes would position an unapproved research material as a therapeutic option, which it is not. Published trial findings are summarised neutrally and with attribution in our overview of the clinical trial evidence, where they are presented as research findings rather than as reasons to buy anything.

What handling and stability differences matter in a lab?

For a laboratory, the practical differences matter as much as the receptor profile. All three compounds are lipophilic acylated peptides of broadly similar size, and they share the handling characteristics typical of that chemistry: supplied lyophilised, sensitive to temperature and light, and requiring cold-chain storage and transit to preserve integrity.

RETApro’s retatrutide is supplied lyophilised, cold-chain shipped, and stored at 2–8 °C away from direct light. Each lot ships with an independently verifiable Certificate of Analysis reporting HPLC purity and mass-spectrometry identity confirmation against the expected molecular weight. Handling guidance here concerns research material only and carries no human-use framing.

One point specific to acylated peptides is worth flagging: because the fatty-acid moiety makes these molecules more lipophilic than unmodified peptides, they can show different solubility and surface-adsorption behaviour during reconstitution than a researcher familiar with simpler peptides might expect. Lot-to-lot consistency in purity and in reported net peptide content is therefore worth tracking rather than assuming.

For how to assess that documentation in any supplier — including what a purity figure does and does not tell you — see our due-diligence guide to evaluating a research peptide supplier.

What is the regulatory status of each compound?

Frequently asked questions